Inflammation Resolution-Targeted Therapies
1 Glycyrrhizin for HMGB1-Mediated PEM Prevention
Certainty: 0.35. Glycyrrhizin (glycyrrhizic acid), the active component of licorice root, is a direct inhibitor of HMGB1’s chemotactic and cytokine-inducing activities. It binds HMGB1 at the Box A/B interface, blocking its interaction with TLR4 and RAGE without affecting DNA-binding functions. Glycyrrhizin is FDA-approved as an oral supplement (standardized to 15-30% glycyrrhizic acid) and available as intravenous glycyrrhizin in Japan (Stronger Neo-Minophagen C) for chronic hepatitis.
Rationale for PEM prevention. HMGB1 translocates from nucleus to extracellular space under oxidative stress, and its redox state determines whether it acts as a pro-inflammatory cytokine (disulfide-HMGB1) or chemotactic factor (fully reduced HMGB1). Exercise-induced oxidative stress during exertion may shift HMGB1 toward the pro-inflammatory disulfide form, triggering the PEM cascade (Ibrahim, Wasim, and Rahman 2026) (Chen et al. 2026).
Mechanism:
- Glycyrrhizin binds HMGB1 directly, blocking TLR4/RAGE binding
- Prevents HMGB1-mediated microglial activation (reducing neuroinflammatory amplification)
- Reduces HMGB1-driven TNF-alpha and IL-1beta release
- Does not affect HMGB1’s nuclear function (DNA chaperone), preserving normal cellular stress responses
- Half-life ~8h; oral bioavailability limited but sufficient
Implementation: Oral glycyrrhizin 200-400 mg (50-100 mg glycyrrhizic acid) taken before planned exertion or at first sign of PEM onset. Drug interaction: glycyrrhizin inhibits 11beta-HSD2, increasing cortisol availability at mineralocorticoid receptors — this mechanism causes pseudoaldosteronism (hypertension, hypokalemia, edema) in susceptible individuals.
Safety considerations:
- Dose-dependent pseudoaldosteronism limits chronic use; avoid in hypertension, hypokalemia, renal impairment
- Concurrent use with thiazide diuretics or loop diuretics increases hypokalemia risk
- Duration: short-term/PRN for PEM prevention rather than continuous daily use
- Carbenoxolone (a glycyrrhetinic acid derivative) has stronger 11beta-HSD2 inhibition; glycyrrhizin is preferred for lower mineralocorticoid activity
Testable prediction: ME/CFS patients receiving glycyrrhizin 200 mg before standardized CPET show reduced plasma disulfide-HMGB1 at 6h post-exercise and reduced PEM severity (PEM duration reduced by >24h) compared to placebo. Falsified if glycyrrhizin does not reduce post-exertional HMGB1 or if HMGB1 reduction does not correlate with PEM improvement.
Cross-reference: HMGB1 DAMP hypothesis (Family 20: Inflammation Resolution and Lipid Mediators, Chapter ME/CFS Through the Lens of Universal Disease Mechanisms). HMGB1-ferroptosis ODE model (SPM Resolution ODE: dSPM”/dt” = k substrate - d * SPM - k pem * PEM, Chapter Causal Hierarchy: Root Causes, Amplifiers, and Consequences). DAMP clearance protocol (C2: DAMP Clearance Protocol — Glycyrrhizin + NAC + Iron Chelation).
2 TUDCA/4-PBA for UPR Inhibition
Certainty: 0.30. The unfolded protein response (UPR) is chronically activated in conditions involving oxidative stress, viral infection, and mitochondrial dysfunction — all documented in ME/CFS. If UPR activation contributes to ME/CFS pathophysiology via IRE1alpha-driven IL-6/TNF-alpha production and PERK-eIF2alpha-mediated NF-kB activation, chemical chaperones that reduce ER stress could provide a therapeutic avenue (Kawano et al. 2023).
Tauroursodeoxycholic acid (TUDCA):
- Endogenous bile acid that acts as a chemical chaperone, stabilizing protein folding in the ER
- Reduces ER stress markers (GRP78, CHOP, spliced XBP1) in multiple disease models
- FDA-approved (as ursodiol) for primary biliary cholangitis at 13-15 mg/kg/day; TUDCA is the taurine-conjugated form with better solubility
- Half-life ~4-6h; well-tolerated (diarrhea most common AE at high doses)
- Neuroprotective in preclinical models of Huntington’s, Parkinson’s, and Alzheimer’s
4-Phenylbutyrate (4-PBA):
- Low molecular weight fatty acid that reduces ER stress by stabilizing protein conformation and enhancing ERAD (ER-associated degradation) capacity
- FDA-approved for urea cycle disorders (Ammonul, Buphenyl) at 9 g/day (divided TID)
- Also acts as a histone deacetylase (HDAC) inhibitor, providing potential epigenetic benefit
- Side effects: taste disturbance, menstrual irregularities, edema; ammonia scavenging effect may alter clinical ammonia monitoring
- Distinguish from sodium phenylbutyrate (which contains sodium load problematic for POTS patients): glycerol phenylbutyrate preferred in ME/CFS
ME/CFS-specific rationale:
- ER stress is the upstream activator of all three UPR arms (IRE1alpha, PERK, ATF6)
- IRE1alpha-XBP1 drives IL-6 and TNF-alpha transcription — directly relevant to ME/CFS inflammatory profile
- PERK-eIF2alpha activates NF-kB via IkB degradation, linking UPR to the broader inflammatory cascade
- ER-mitochondria contact sites (MAMs) regulate calcium transfer; ER stress at MAMs impairs mitochondrial function directly
- The UPR connects to sleep disruption (Kawano et al. (Kawano et al. 2023) demonstrated ER proteostasis signals regulate sleep), providing a mechanistic link to ME/CFS sleep pathology
- Bistable UPR switching (once activated, persists without ongoing trigger — see HMGB1-Ferroptosis Coupled ODE System) predicts that early intervention before irreversible commitment to chronic UPR may be most effective
Implementation:
- TUDCA: 500-1000 mg/day (typically 15 mg/kg) for 12 weeks; taken with food to improve absorption
- 4-PBA (glycerol phenylbutyrate): 3-6 g/day divided TID (half the standard urea cycle dose to reduce side effect burden); requires monitoring of phenylacetate levels
- Combination TUDCA + 4-PBA may provide additive benefit through different chaperone mechanisms
Testable prediction: ME/CFS patients receiving TUDCA 1g/day show reduced ER stress markers (GRP78, sXBP1, CHOP) in PBMCs at 12 weeks, correlating with reduced TNF-alpha and IL-6 levels and improved fatigue scores. Adding 4-PBA provides additional reduction in CHOP (pro-apoptotic marker) not seen with TUDCA alone. Falsified if UPR markers are normal at baseline or if TUDCA/4-PBA does not suppress ME/CFS UPR despite target engagement.
Cross-reference: IRE1alpha bistable switch model (HMGB1-Ferroptosis Coupled ODE System, Chapter Causal Hierarchy: Root Causes, Amplifiers, and Consequences). UPR/ER stress section (Family 13: Protein Homeostasis and Degradation, Chapter ME/CFS Through the Lens of Universal Disease Mechanisms). ER stress resolution protocol (C3: ER Stress Resolution — TUDCA + Fasting + Huperzine A).
3 tVNS for SPM Induction
Certainty: 0.35. Vagal signaling via the cholinergic anti-inflammatory pathway stimulates resolvin production: alpha7-nAChR activation on macrophages and monocytes promotes SPM biosynthesis through a STAT3-dependent pathway. tVNS (transcutaneous vagus nerve stimulation) applied to the auricular branch at the cymba conchae activates this pathway without surgical implantation.
Rationale:
- The vagus nerve → alpha7-nAChR → SPM synthesis axis links autonomic function to active inflammation resolution
- ME/CFS patients have reduced vagal tone (low HRV, blunted baroreflex sensitivity) predicting impaired baseline SPM production
- tVNS is non-invasive, well-tolerated, and has preliminary evidence in ME/CFS (Yu 2022, Natelson 2022)
- SPM induction represents a distinct mechanism from tVNS’s other effects (autonomic stabilization, mast cell modulation, BBB permeability enhancement)
Mechanism:
- Auricular tVNS activates vagal afferents → nucleus tractus solitarius → vagal efferent activation
- Efferent vagal signaling via alpha7-nAChR on macrophages suppresses TNF-alpha while simultaneously promoting SPM biosynthesis
- Resolvins (RvD1, RvE1), protectins (PD1), and maresins (MaR1) are elevated in plasma within 2-4h of vagus nerve stimulation in animal models
- This SPM-mediated anti-inflammatory effect is qualitatively different from TNF-alpha suppression alone — SPMs actively clear cellular debris via efferocytosis and promote tissue repair
Implementation:
- tVNS device: left ear cymba conchae, 25 Hz, 200-300 µs pulse width, 5 min 1-2x daily
- Timing for SPM induction: once daily in the morning (SPMs peak 2-4h post-stimulation)
- Additional session before planned exertion for PEM prevention
- Duration: 4-8 weeks for baseline SPM elevation; ongoing for maintenance
- Consider combining with omega-3 supplementation (SPM precursor provision) and low-dose aspirin (AT-SPM generation) for synergistic SPM enhancement
Testable prediction: ME/CFS patients using daily tVNS for 8 weeks show elevated plasma SPM levels (RvD1, RvE1, MaR1; >50% increase from baseline) that correlate with improved HRV (RMSSD +20%) and reduced PEM duration. The SPM elevation is detectable within 4 weeks and plateaus by 8 weeks. Falsified if SPM levels do not increase despite HRV improvement (suggesting vagal tone improvement alone is insufficient for SPM upregulation).
Cross-reference: SPM deficiency hypothesis (Family 20: Inflammation Resolution and Lipid Mediators). Omega-3 and aspirin SPM strategy (Aspirin + Omega-3 for SPM Precursor Provision, Chapter Speculative Mechanistic Hypotheses). SPM restoration protocol (C1: SPM Restoration Protocol — Aspirin + Omega-3 + tVNS + Diet).
4 Protocol C1: SPM Restoration Protocol
Certainty: 0.30. Combines four SPM-enhancing interventions targeting complementary nodes in the resolution pathway:
- Aspirin 81 mg daily (morning): Acetylates COX-2, enabling AT-SPM (aspirin-triggered resolvin) synthesis
- Omega-3 (EPA 2-4g + DHA 1-2g daily): Provides SPM substrate; re-esterified triglyceride form for optimal absorption
- tVNS 5 min daily (morning): Activates vagal-alpha7-nAChR-SPM synthesis pathway
- SPM-supportive diet: Omega-3-rich foods (fatty fish, flax, chia), polyphenol-rich foods (berries, olive oil) for additional SPM precursor and anti-inflammatory support; limit omega-6 excess (reduce processed seed oils)
Rationale for combination: Each component targets a different bottleneck in the SPM synthesis pathway: substrate provision (omega-3), enzymatic conversion (aspirin-acetylated COX-2), neural activation of SPM biosynthesis (tVNS), and dietary support for overall resolution capacity.
Safety:
- Aspirin + omega-3 combination increases bleeding risk slightly (theoretical) — monitor for bruising, GI bleeding
- tVNS contraindicated in cardiac arrhythmias
- High-dose omega-3 may cause fishy aftertaste, mild GI upset, and prolong bleeding time at very high doses (>4g combined EPA+DHA)
- Monitor for aspirin intolerance
Testable prediction: The combination produces greater SPM elevation (RvD1+RvE1+MaR1 increase >100%) than any single component alone, with additive effects. PEM severity and duration reduced by >40% in the combination group at 12 weeks.
Cross-reference: Individual components (Aspirin + Omega-3 for SPM Precursor Provision, Transcutaneous Vagal Nerve Stimulation for SPM Induction). DAMP clearance protocol (C2: DAMP Clearance Protocol — Glycyrrhizin + NAC + Iron Chelation, below).
5 Protocol C2: DAMP Clearance Protocol
Certainty: 0.25. Targets extracellular DAMP accumulation through three complementary mechanisms:
- Glycyrrhizin 200-400 mg daily (short-term/PRN): Direct HMGB1 neutralization
- NAC 600-1200 mg daily: Glutathione precursor for enhanced antioxidant capacity; reduces DAMP generation by neutralizing ROS; supports GPX4 activity for ferroptosis prevention
- Iron chelation (low-dose deferiprone or curcumin with piperine): Reduces labile iron available for Fenton chemistry, decreasing ferroptosis-driven DAMP release
Rationale for combination:
- Glycyrrhizin neutralizes extracellular HMGB1 (the DAMP) after it is released
- NAC reduces oxidative stress that triggers HMGB1 release (reducing DAMP generation)
- Iron chelation reduces the lipid peroxidation-ferroptosis-DAMP release cascade
- The combination addresses DAMP accumulation at three points: generation (NAC, iron chelation), release (iron chelation), and extracellular activity (glycyrrhizin)
Safety:
- Glycyrrhizin: pseudoaldosteronism risk limits duration to 4-8 weeks; monthly BP and K+ monitoring required
- NAC: generally well-tolerated; rare bronchospasm; may cause GI upset at high doses
- Iron chelation: deferiprone carries risk of agranulocytosis (weekly CBC monitoring required); curcumin with piperine is safer but less potent; avoid in patients without documented iron overload
- DAMP clearance may transiently worsen symptoms (“herx-like” reaction) as tissue repair releases sequestered DAMPs
Testable prediction: ME/CFS patients receiving the triple protocol for 8 weeks show reduced plasma DAMP levels (HMGB1 -40%, 4-HNE -30%, mtDNA -25%) and improved fatigue scores (SF-36 PF +15 points) compared to placebo. NAC alone reduces oxidative markers but not HMGB1; glycyrrhizin alone reduces HMGB1 but not oxidative markers; the combination is required for both.
Cross-reference: HMGB1-DAMP hypothesis (Family 20: Inflammation Resolution and Lipid Mediators). HMGB1-ferroptosis ODE model (SPM Resolution ODE: dSPM”/dt” = k substrate - d * SPM - k pem * PEM). Glycyrrhizin speculation (Glycyrrhizin for HMGB1-Mediated PEM Prevention).
6 Albumin Infusion for DAMP Sequestration and Iron Buffering
Certainty: 0.25. Intravenous albumin infusion (25% albumin, 100 mL weekly × 4) provides three complementary anti-inflammatory mechanisms from a single, well-established intervention already used in critical care: (a) iron-binding capacity — albumin binds free iron, reducing Fenton chemistry-driven ROS generation and ferroptosis; (b) HMGB1 sequestration — albumin directly binds and neutralizes extracellular HMGB1, the central DAMP implicated in PEM amplification (Section Family 20: Inflammation Resolution and Lipid Mediators); (c) thiol-mediated antioxidant activity — albumin’s free cysteine (Cys34) is a major plasma thiol reservoir with radical-scavenging capacity. These three effects — iron buffering, DAMP neutralization, and antioxidant activity — address distinct nodes of the ferroptosis-DAMP-oxidative stress cycle with one intervention. Important parsimony caveat: these “three mechanisms” may represent three descriptions of the same underlying redox pathway (iron buffering is antioxidant activity; HMGB1 sequestration operates through redox state) rather than dissociable, independent targets. The triple-mechanism claim is an organizational convenience, not evidence of three separate therapeutic modes. A pilot study design (n=10, pre/post) would measure free iron, ferritin, HMGB1, isoprostanes, and fatigue scores before and after 4 weekly infusions.
Safety:
- Albumin infusion is well-tolerated in critical care and volume expansion indications
- Contraindications: congestive heart failure, severe anemia, sensitivity to albumin
- Volume expansion may temporarily worsen POTS in hypovolemic-predominant patients
- This is a research-stage concept — no ME/CFS data exist
Testable prediction: 4 weekly albumin infusions reduce serum free iron and HMGB1 by ≥25%, reduce isoprostanes by ≥20%, and improve fatigue (SF-36 PF ≥5 points) compared to baseline in a pre/post pilot study. Falsified if free iron AND HMGB1 do not decrease — if only DAMP or only iron improves, the “triple-mechanism” claim is refuted; single-mechanism efficacy would require separate hypothesis reformulation.
Cross-reference: HMGB1 DAMP hypothesis (Family 20: Inflammation Resolution and Lipid Mediators, Chapter ME/CFS Through the Lens of Universal Disease Mechanisms). DAMP clearance protocol C2 (C2: DAMP Clearance Protocol — Glycyrrhizin + NAC + Iron Chelation). Iron/ferroptosis mechanism (Chapter Energy Metabolism and Mitochondrial Function). Hepcidin-iron trap hypothesis (ch14b).
7 Protocol C3: ER Stress Resolution Protocol
Certainty: 0.20. Combines three ER stress-reducing strategies:
- TUDCA 500-1000 mg/day: Chemical chaperone stabilizing ER protein folding, reducing UPR activation
- Intermittent fasting or time-restricted eating (16:8 daily or 5:2 weekly): Autophagy enhancement; fasting reduces ER load by limiting protein synthesis and promoting autophagic clearance of misfolded proteins
- Huperzine A 50-100 mcg BID: Acetylcholinesterase inhibitor; enhances cholinergic signaling, which suppresses PERK-eIF2alpha via alpha7-nAChR; may also reduce ER calcium depletion through nicotinic receptor modulation
Rationale for combination:
- TUDCA reduces ER stress directly (chaperone mechanism)
- Intermittent fasting reduces protein synthesis flux into the ER (substrate reduction), simultaneously activating autophagy for clearance
- Huperzine A provides cholinergic UPR suppression through a distinct (neuronal-immune) mechanism
- The combination addresses ER stress through chaperone enhancement (TUDCA), substrate reduction (fasting), and neural regulation (huperzine A)
Safety:
- TUDCA: generally well-tolerated; diarrhea at high doses; long-term safety in ME/CFS unknown
- Intermittent fasting: may worsen orthostatic intolerance and POTS symptoms; contraindicated in underweight patients; monitor for hypoglycemia
- Huperzine A: cholinergic side effects (nausea, diarrhea, muscle cramps, bradycardia); narrow therapeutic window; avoid with concurrent cholinergic drugs; beta-blockers may compound bradycardia risk
Testable prediction: The combination reduces PBMC UPR markers (GRP78, sXBP1, CHOP) by >50% at 12 weeks in ME/CFS patients with elevated baseline UPR markers. TUDCA alone reduces GRP78 but not sXBP1; TUDCA + fasting is required for both markers.
Cross-reference: TUDCA/4-PBA speculation (TUDCA and 4-Phenylbutyrate for ER Stress/UPR Inhibition). IRE1alpha bistable switch model (HMGB1-Ferroptosis Coupled ODE System). Autophagy-heat switch (Heat-Induced Autophagy Switch: Selective-to-Bulk Transition via HSP70 Redistribution, Chapter Energy Metabolism and Mitochondrial Function).
8 Ziritaxestat/Autotaxin-LPA for Fibrotic-Neuroinflammatory Crosstalk
Certainty: 0.20. Autotaxin converts LPC to LPA, a bioactive lipid signaling through LPA1-6 receptors that drives TGF-beta1 induction, fibroblast activation, ECM deposition, and microglial activation. Ziritaxestat (Phase III IPF) provides a clinically-ready ATX inhibitor with established safety. If ATX-LPA is elevated in ME/CFS, it provides a druggable bridge between fibrotic pathology (capillary basement membrane thickening) and neuroinflammation (LPA1-mediated microglial activation). See Ziritaxestat/Autotaxin-LPA Inhibition for Fibrotic-Neuroinflammatory Crosstalk (Chapter Speculative Mechanistic Hypotheses) for full mechanism. Falsifiable: ATX activity and LPA levels are elevated in ME/CFS; ziritaxestat reduces LPA and improves fatigue in ATX-high patients.